Answers are grounded in this paper and cite their sources.
Since the COVID-19 pandemic has started in December 2019, millions of people have been infected all over the world and few vaccines have been invented recently. Extremely rare, Guillain-Barre Syndrome (GBS) was reported as a neurological complication after H1N1 flu vaccination. Currently, Pfizer and AstraZeneca vaccines are available to prevent infection with COVID-19. The first case of post-COVID-19 vaccine GBS has been detected in a secondary care hospital after vaccination with AstraZeneca. A 67-year-old man presented with an acute progressive ascending flaccid symmetrical motor neuropathy, and bilateral facial weakness which developed two weeks after receiving the first dose of AstraZeneca COVID-19 vaccine. His cerebrospinal fluid findings, nerve conduction result, and MRI brain result were all in favour of GBS diagnosis. The patient’s workup for all known infections associated with immune-mediated GBS was negative.
No takes yet. Share an insight, caveat, or question.
Khalil et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: